AbbVie Inc. (ABBV) just dropped some encouraging news for multiple myeloma patients and their doctors. On Thursday, the pharma giant shared topline results from its Phase 3 CERVINO trial, which tested an investigational drug called etentamig in people with relapsed or refractory multiple myeloma. The drug didn't just hold its own against standard therapies; it beat them on the two big measures that matter most: how often tumors shrank and how long patients went without the disease progressing.
Let's dig into the numbers. After a median follow-up of 11.4 months, the study looked at 393 patients who had already been through a median of three prior treatment lines. These are folks who've run out of easy options, so any win here is meaningful. Among those getting etentamig, 74% saw their cancer respond, compared to just 45.7% for those on standard available therapies. That's a hefty gap.
Progression-free survival also got a significant boost across every subgroup the researchers checked. And the 12-month overall survival rate hit 87.9% for etentamig, versus 72% for standard care. Now, a quick caveat: those survival numbers haven't yet crossed the prespecified boundary for statistical significance, so we should temper our enthusiasm a bit. But the trend is clearly pointing in the right direction.
Safety is always the other side of the coin, and here etentamig looks pretty reasonable. The dosing schedule is a single step-up dose followed by monthly infusions, which is convenient for patients. Severe infections (grade 3 or 4) showed up in 27.7% of the etentamig group, compared to 19.2% for standard therapy. That sounds worse, but here's the twist: fatal infections (grade 5) were actually lower with etentamig, at 1.5% versus 3.1% for standard care. So while the drug might cause more non-fatal infections, it seems to be less deadly overall.
Cytokine release syndrome, that immune-system overreaction that's been a headache for other cancer drugs, stayed low at 28.3%, and none of those cases reached grade 3 or higher. Only one patient had mild neurotoxicity. And when it came to side effects forcing patients to stop treatment, only 3.6% of etentamig users dropped out, versus 9.6% for standard therapies. That's a big deal for quality of life.
Given these strong interim results, the Independent Data Monitoring Committee recommended unblinding the study, which basically means they think the data is solid enough to share with everyone. AbbVie now plans to talk with global regulators about what comes next, likely paving the way for a submission.
As for the stock, AbbVie shares were down a hair, 0.31%, to $260.89 at the time of writing on Thursday. The stock is hovering near its 52-week high of $267.47, so investors seem cautiously optimistic. It's a reminder that even good clinical data doesn't always move the needle in real time, but the long-term picture for etentamig could be bright.
